Oct 28, 2024
Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024
Oct 17, 2024
Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial
Oct 10, 2024
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
Oct 03, 2024
Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer
Sep 24, 2024
Immutep Receives A$3.6 million R&D Tax Incentive from French Government
